Related Experiment Video
Updated: Jul 8, 2025
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.7K
Retzius-Sparing Robotic-Assisted Prostatectomy: Technical Challenges for Surgeons and Key Prospective Refinements
Simone Ferretti1, Paolo Dell'Oglio2,3,4, Davide Ciavarella1
1Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Urology Unit, Chieti, Italy.
Research and Reports in Urology
|December 18, 2023
Summary
Retzius-sparing radical prostatectomy (RS-RARP) offers faster urinary continence recovery compared to standard anterior approaches for prostate cancer. Evidence suggests RS-RARP is safe and effective, even in complex cases, with comparable oncological outcomes.
Area of Science:
- Urology
- Surgical Oncology
- Robotic Surgery
Background:
- Robotic-assisted radical prostatectomy (RARP) is a standard treatment for localized prostate cancer.
- Various RARP techniques aim to enhance oncological and functional results.
- The Retzius-sparing RARP (RS-RARP) approach, introduced in 2010, utilizes a posterior route to preserve structures crucial for continence and potency.
Purpose of the Study:
- To evaluate the efficacy and safety of the Retzius-sparing RARP (RS-RARP) technique.
- To compare RS-RARP outcomes with the standard anterior RARP approach.
- To address concerns regarding positive surgical margins in RS-RARP.
Main Methods:
- Systematic reviews and meta-analyses comparing RS-RARP with standard anterior RARP.
- Analysis of randomized controlled trials.
- Evaluation of evidence regarding surgical margins and outcomes in various patient risk groups.
Main Results:
- RS-RARP demonstrates a significant advantage in early urinary continence recovery compared to standard anterior RARP.
- Perioperative and long-term oncological outcomes are comparable between the two approaches.
- Concerns about increased positive surgical margins with RS-RARP are based on low-certainty evidence, often from initial learning curves.
Conclusions:
- RS-RARP is a safe and feasible technique for prostate cancer treatment.
- The approach shows particular promise for early recovery of urinary continence.
- Recent evidence supports the use of RS-RARP in diverse clinical scenarios, including high-risk patients and post-transurethral resection of the prostate settings.
